FDA Approves First TROP2-Directed ADC for Triple-Negative Breast Cancer

The U.S. Food and Drug Administration (FDA) has approved datopotamab deruxtecan-dlnk (marketed as Datroway) as the first TROP2-directed antibody drug conjugate for the first-line treatment of unresectable or metastatic triple-negative breast cancer (TNBC) in patients who are ineligible for PD-1/PD-L1 inhibitor therapy. The approval marks a significant advancement in treatment options for a aggressive cancer subtype with limited targeted therapies.

The decision follows the FDA’s grant of priority review and is based on results from the phase 3 TROPION-Breast02 trial, which were presented at the 2025 European Society for Medical Oncology (ESMO) Congress and published in Annals of Oncology. The trial demonstrated the drug’s efficacy in patients with advanced TNBC, a disease characterized by rapid progression and poor long-term outcomes.

Why This Matters for Triple-Negative Breast Cancer Patients

Triple-negative breast cancer accounts for approximately 10–15% of all breast cancer diagnoses and is defined by the absence of estrogen receptors, progesterone receptors, and HER2 overexpression. Historically, treatment options have been limited, relying heavily on chemotherapy and, more recently, immune checkpoint inhibitors like PD-1/PD-L1 inhibitors. However, many patients either do not respond to these therapies or develop resistance, leaving a critical unmet need.

Datopotamab deruxtecan represents a new class of treatment known as an antibody-drug conjugate (ADC). This approach combines a monoclonal antibody targeting the TROP2 protein—which is overexpressed in TNBC—with a potent cytotoxic payload. The drug is designed to deliver chemotherapy directly to cancer cells, potentially reducing systemic toxicity while improving tumor response rates.

Key Details of the FDA Approval

The approval was supported by data from the TROPION-Breast02 trial, which enrolled patients with unresectable or metastatic TNBC who had not received prior systemic therapy for their advanced disease. The trial’s primary endpoint was progression-free survival (PFS), a key measure of how long the treatment delays disease progression. While exact numerical results were not provided in the initial reporting, the FDA’s decision indicates that the trial met its primary efficacy endpoint, providing a meaningful benefit over standard therapies.

The drug’s safety profile was also evaluated, with common adverse events typically associated with ADCs, such as neutropenia, nausea, and fatigue. The FDA’s approval includes a Risk Evaluation and Mitigation Strategy (REMS) to monitor for serious side effects, including interstitial lung disease, a known risk with certain ADCs.

Broader Implications for Cancer Treatment

This approval builds on the FDA’s growing focus on targeted therapies for rare and aggressive cancers. In recent years, the agency has accelerated reviews for novel treatments in oncology, including other ADCs like trastuzumab deruxtecan (Enhertu) for HER2-positive breast cancer and sacituzumab govitecan (Trodelvy) for triple-negative breast cancer. Datopotamab deruxtecan’s approval further expands the toolkit for oncologists treating TNBC, particularly for patients who have exhausted other options.

Manufactured by AstraZeneca and Daiichi Sankyo, Datroway is expected to be available for prescription in the coming weeks. The companies have also initiated discussions with payers and healthcare systems to ensure timely access for eligible patients.

What Comes Next: Uncertainties and Ongoing Research

While the approval is a milestone, several questions remain about the drug’s long-term efficacy and optimal use. For instance, head-to-head comparisons with existing PD-1/PD-L1 inhibitors are lacking, as the trial only included patients ineligible for those therapies. The durability of responses and overall survival benefits will require longer follow-up data.

Ongoing trials, such as TROPION-Breast03, are investigating datopotamab deruxtecan in earlier-stage TNBC and in combination with other immunotherapies. These studies may further clarify its role in the treatment paradigm.

For patients, the approval offers a new option but does not replace the need for personalized treatment planning. Oncologists will need to weigh the benefits and risks of Datroway against other available therapies, including clinical trials, based on individual patient profiles.

A Step Forward, But Challenges Remain

The FDA’s approval of datopotamab deruxtecan underscores progress in precision oncology, particularly for patients with limited treatment options. However, the journey toward curing TNBC is far from over. Advocacy groups, such as the Triple-Negative Breast Cancer Foundation, continue to push for expanded research funding and access to innovative therapies. As with all cancer treatments, real-world evidence and continued innovation will be critical to improving outcomes for those affected by this challenging disease.